This site contains promotional information intended only for healthcare professionals resident in Great Britain

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Maternal ImmunisationMaternal
Immunisation
Maternal Immunisation HomepageSafety ProfileDosing
Older AdultsOlder AdultsOlder Adults HomepageSafety ProfileDosingPreparationUseful ResourcesUseful
Resources
VideosMaterials

The content of this website has been produced in line with the ABRYSVO®(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain only. ABRYSVO▼ Prescribing Information for Great Britain click here. ABRYSVO▼ Prescribing Information for Northern Ireland click here.

ABRYSVO is a maternal RSV vaccine that can help protect infants against serious consequences of RSV from birth and through 6 months of life.1


 

RSV is a leading cause of lower respiratory tract infection (LRTI)-related hospitalisations in infants in the UK.


Infants are most vulnerable to RSV hospitalisation in the first 6 months of life.2
In England, it is estimated that, each year, RSV in infants under 6 months leads to:3


 

64,000 GP appointments


 

13,000 RSV associated hospitalisations

ABRYSVO is a maternal RSV vaccine that can help protect infants against serious consequences of RSV from birth and through 6 months of life.1
 

A pregnant woman receives ABRYSVO during 28-36 weeks of gestation.1

The pregnant woman's immune system produces antibodies, which are passed through the placenta to the foetus.4

The infant is born with maternal antibodies helping to protect against RSV infection.4

This content is for Great Britain only. If you reside in Northern Ireland, please refer to the Summary of Product Characteristics (SmPC) for more information.
Learn more about RSV & ABRYSVO with 5-minute eModules eModule 1: Understand RSV disease and the at-risk populations Loading eModule 2: What is ABRYSVO?
Dosing


Understand more about the dosing, administration and storage of ABRYSVO for maternal patients.

Learn moreLoading

Safety Profile


Learn more about the safety information of ABRYSVO in pregnant women. 

Learn moreLoading

Useful Resources


Explore the ABRYSVO resources section for useful videos and materials.

VideosLoading Materials
ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain. Available at: https://www.medicines.org.uk/emc/product/15309.Reeves, R. M. et al. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England. A data linkage modelling study. J Infect, 2019. 78: 468-475.Cromer, D. van Hoek, A. J. Newall, A. T. Pollard, A. J. Jit, M. Burden of paediatric respiratory syncytial virus disease and potential effect of different effect immunisation strategies: a modelling and cost effectiveness analysis for England. Lancet Public Health. 2017. 2(8): e367-e374.Cinicola, B. et al. The Protective Role of Maternal Immunization in Early Life. Front Pediatr. 2021. 28;9:638871. 
PP-A1G-GBR-0002. February 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​